Morepen Laboratories (NSE:MOREPENLAB) Cash-to-Debt: N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MOREPENLAB Morepen Laboratories Ltd NSE:MOREPENLAB
66 GF Score
Price ₹96.01
GF Value ₹54.31
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Morepen Laboratories Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Morepen Laboratories's cash to debt ratio for the quarter that ended in Jun. 2026 was N/A.

The historical rank and industry rank for Morepen Laboratories's Cash-to-Debt or its related term are showing as below:

NSE:MOREPENLAB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14   Med: 1.01   Max: 12.06
Current: 0.52

During the past 13 years, Morepen Laboratories's highest Cash to Debt Ratio was 12.06. The lowest was 0.14. And the median was 1.01.

NSE:MOREPENLAB's Cash-to-Debt is ranked worse than
61.05% of 950 companies
in the Drug Manufacturers industry
Industry Median: 0.98 vs NSE:MOREPENLAB: 0.52

Morepen Laboratories  (NSE:MOREPENLAB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Morepen Laboratories Cash-to-Debt Related Terms

Morepen Laboratories Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for Morepen Laboratories's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Morepen Laboratories Cash-to-Debt Chart

Morepen Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.86 0.58 1.00 0.52

Morepen Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.59 N/A 0.52 N/A

NSE:MOREPENLAB vs ZTS: Cash-to-Debt Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Morepen Laboratories Cash-to-Debt vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Morepen Laboratories's Cash-to-Debt falls into.


NSE:MOREPENLAB
66GF Score
Morepen Laboratories Ltd NSE:MOREPENLAB
Cash-to-Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Morepen Laboratories Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Morepen Laboratories's Cash to Debt Ratio for the fiscal year that ended in Mar. 2026 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=1076.749 / (699.938 + 1378.614)
=0.52

Morepen Laboratories's Cash to Debt Ratio for the quarter that ended in Jun. 2026 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued. The current stock price of ₹96.01 is trading 76.8% above its estimated GF Value™ of ₹54.31. GuruFocus considers Morepen Laboratories to be Significantly Overvalued.

Key valuation signals for NSE:MOREPENLAB:

  • Cash-to-Debt: N/A
  • GF Value™: ₹54.31 vs. price of ₹96.01 (76.8% above fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Morepen Laboratories Business Description

Other Exchanges 500288:India
Address Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
66GF Score

Get the complete analysis for NSE:MOREPENLAB

Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹96.01
Price
₹54.31
GF Value